Acorah Software Products - Accounts Production 19.3.550 false true true 31 December 2024 1 January 2024 false 1 January 2025 31 December 2025 31 December 2025 08616211 Mr David Schilansky Ariceum Therapeutics GmbH Robert-Rossle-Str. 10, 13125 Berlin, Germany true iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 08616211 2024-12-31 08616211 2025-12-31 08616211 2025-01-01 2025-12-31 08616211 frs-core:CurrentFinancialInstruments 2025-12-31 08616211 frs-core:Non-currentFinancialInstruments 2025-12-31 08616211 frs-core:ComputerEquipment 2025-12-31 08616211 frs-core:ComputerEquipment 2025-01-01 2025-12-31 08616211 frs-core:ComputerEquipment 2024-12-31 08616211 frs-core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2025-01-01 2025-12-31 08616211 frs-core:OtherResidualIntangibleAssets 2025-12-31 08616211 frs-core:OtherResidualIntangibleAssets 2024-12-31 08616211 frs-core:WithinOneYear 2025-12-31 08616211 frs-core:SharePremium 2025-12-31 08616211 frs-core:ShareCapital 2025-12-31 08616211 frs-core:RetainedEarningsAccumulatedLosses 2025-12-31 08616211 frs-bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 08616211 frs-bus:FilletedAccounts 2025-01-01 2025-12-31 08616211 frs-bus:SmallEntities 2025-01-01 2025-12-31 08616211 frs-bus:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 08616211 frs-bus:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 08616211 1 2025-01-01 2025-12-31 08616211 frs-core:CostValuation 2024-12-31 08616211 frs-core:CostValuation 2025-12-31 08616211 frs-core:ProvisionsForImpairmentInvestments 2024-12-31 08616211 frs-core:ProvisionsForImpairmentInvestments 2025-12-31 08616211 frs-bus:Director1 2025-01-01 2025-12-31 08616211 frs-countries:EnglandWales 2025-01-01 2025-12-31 08616211 2023-12-31 08616211 2024-12-31 08616211 2024-01-01 2024-12-31 08616211 frs-core:CurrentFinancialInstruments 2024-12-31 08616211 frs-core:Non-currentFinancialInstruments 2024-12-31 08616211 frs-core:BetweenOneFiveYears 2024-12-31 08616211 frs-core:WithinOneYear 2024-12-31 08616211 frs-core:SharePremium 2024-12-31 08616211 frs-core:ShareCapital 2024-12-31 08616211 frs-core:RetainedEarningsAccumulatedLosses 2024-12-31
Registered number: 08616211
Theragnostics Limited
Unaudited Financial Statements
For The Year Ended 31 December 2025
Finerva
Contents
Page
Balance Sheet 1—2
Notes to the Financial Statements 3—6
Page 1
Balance Sheet
Registered number: 08616211
2025 2024
Notes £ £ £ £
FIXED ASSETS
Tangible Assets 5 253 421
Investments 6 1 1
254 422
CURRENT ASSETS
Debtors 7 6,751,058 5,565,647
Cash at bank and in hand 441,263 253,242
7,192,321 5,818,889
Creditors: Amounts Falling Due Within One Year 8 (3,914,135 ) (927,740 )
NET CURRENT ASSETS (LIABILITIES) 3,278,186 4,891,149
TOTAL ASSETS LESS CURRENT LIABILITIES 3,278,440 4,891,571
Creditors: Amounts Falling Due After More Than One Year 9 - (3,180,228 )
NET ASSETS 3,278,440 1,711,343
CAPITAL AND RESERVES
Called up share capital 10 3,142,597 1,342,597
Share premium account 9,231,865 9,231,865
Profit and Loss Account (9,096,022 ) (8,863,119 )
SHAREHOLDERS' FUNDS 3,278,440 1,711,343
Page 1
Page 2
For the year ending 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
The financial statements were approved by the board of directors on 4 September 2026 and were signed on its behalf by:
Mr David Schilansky
Director
4 September 2026
The notes on pages 3 to 6 form part of these financial statements.
Page 2
Page 3
Notes to the Financial Statements
1. General Information
Theragnostics Limited is a private company,  limited by shares, incorporated in England & Wales, registered number 08616211 . The registered office is Spaces Oxford Street, Mappin House, 4 Winsley Street, London, W1W 8HF.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements are prepared under the historical cost convention and in accordance with the FRS 102 Section 1A Small Entities - The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.
2.2. Going Concern Disclosure
The company’s financial statements have been prepared on a going concern basis on the grounds  that current and future sources of funding or support will be more than adequate for the company’s needs. In assessing going concern, the directors have prepared cashflow forecasts. Based on these forecasts, the directors have a reasonable expectation that the company will continue as a going concern and is able to meet all of its obligations as they fall due for a minimum of 12 months from the date of approval of these financial statements. The financial statements do not include any adjustments that may arise from any significant changes in the assumptions used in preparing the forecasts.
2.3. Turnover
Revenue is recognised to the extent there is probable economic benefits will flow to the company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Revenue from a contract to provide services is recognised in the period in which the services are provided.

2.4. Intangible Fixed Assets and Amortisation - Other Intangible
Research and development costs

Expenditure on research activities is recognised within profit or loss as an expense is incurred.

Purchased intangible assets consist of licences

Purchased intangible assets are initially recognised at cost. After recognition, intangible assets are measured at cost less any accumulated amortisation and impairment losses.

All intangible assets are considered to have a finite useful life. The useful life of an intangible asset that arises from contractual or other legal rights does not exceed the period of the contractual or other legal rights, but may
be shorter depending on the period over which the entity expects to use the asset.

The estimated useful lives are as follows:

Licences – 5 years on a straight line basis

At each reporting date the company assesses whether there is any indication of impairment. If such indications exists, the recoverable amount of the asset is determined which is the higher of its fair value less costs to sell and its value in use. Any impairment loss is recognised immediately as an expense within profit or loss.

2.5. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses.  Depreciation  is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:
Computer Equipment 3 years
Page 3
Page 4
2.6. Leasing and Hire Purchase Contracts
Leases in which the company assumes substantially all the risks and rewards of ownership of the leased asset are classified as finance leases. All other leases are classified as operating leases.

Payments (excluding costs for services and insurance) made under operating leases are recognised in the profit and loss account on a straight-line basis over the term of the lease unless the payments to the lessor are structured to increase in line with expected general inflation; in which case the payments related to the structured increases are recognised as incurred. Lease incentives received are recognised in profit and loss over the term of the lease as an integral part of the total lease expenses.
2.7. Financial Instruments
Trade and other debtors / creditors
Trade and other debtors are recognised initially at transaction prices less attributable transaction costs. Trade and other creditors are recognised initially at transaction price plus attributable transaction costs. Subsequent to initial recognition they are measured at amortised cost using the effective interest method, less any impairment losses in the case of trade debtors. If the arrangement constitutes a financing transaction, for example if payment is deferred beyond normal business terms, then it is measured at the present value of future payments discounted at a market rate of interest for a similar debt instrument.
Investments
Investments in subsidiaries are held at cost less accumulated impairment losses.
Impairment of financial assets
Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found an impairment loss is recognised within profit or loss.
For financial assets that are measured at amortised cost, the impairment loss is measured as the difference between the asset’s carrying amount and the present value of estimated cash flows discounted at the asset’s original effective interest rate.
For financial assets measured at cost less impairment, the impairment loss is measured as the difference between the asset’s carrying amount and the best estimate of the amount that the company would receive for the asset if it were to be sold at the balance sheet date.
2.8. Foreign Currencies
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date.   Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
2.9. Taxation
Income tax expense represents the sum of the tax currently payable.
The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other year and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.
Current tax for the year is recognised in profit or loss.
2.10. Pensions
The company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the company pays fixed contributions in a separate entity. Once the contributions have been paid the company has no further payment obligations. The contributions are recognised as an expense in profit or loss in the periods during which services are rendered by employees.
2.11. Related party exemption
The company has taken advantage of the exemption available under FRS 102 not to disclose related party transactions with wholly owned subsidiaries within the group.
Page 4
Page 5
3. Average Number of Employees
Average number of employees during the year was 1 (2024: 2)
1 2
4. Intangible Assets
Other
£
Cost
As at 1 January 2025 2,608,045
As at 31 December 2025 2,608,045
Amortisation
As at 1 January 2025 2,608,045
As at 31 December 2025 2,608,045
Net Book Value
As at 31 December 2025 -
As at 1 January 2025 -
5. Tangible Assets
Computer Equipment
£
Cost
As at 1 January 2025 505
As at 31 December 2025 505
Depreciation
As at 1 January 2025 84
Provided during the period 168
As at 31 December 2025 252
Net Book Value
As at 31 December 2025 253
As at 1 January 2025 421
6. Investments
Other
£
Cost or Valuation
As at 1 January 2025 1
As at 31 December 2025 1
Provision
As at 1 January 2025 -
As at 31 December 2025 -
...CONTINUED
Page 5
Page 6
Net Book Value
As at 31 December 2025 1
As at 1 January 2025 1
7. Debtors
2025 2024
£ £
Due within one year
Amounts owed by group undertakings 6,282,548 5,014,669
Other debtors 468,510 550,978
6,751,058 5,565,647
8. Creditors: Amounts Falling Due Within One Year
2025 2024
£ £
Trade creditors 39,842 316,851
Bank loans and overdrafts 4,167 10,000
Amounts owed to group undertakings 3,551,469 113,596
Other creditors 318,657 481,485
Taxation and social security - 5,808
3,914,135 927,740
Included within other creditors are outstanding pension contributions of £0 (2024: £514)
9. Creditors: Amounts Falling Due After More Than One Year
2025 2024
£ £
Bank loans - 4,167
Amounts owed to group undertakings - 3,176,061
- 3,180,228
11. Other Commitments
The total of future minimum lease payments under non-cancellable operating leases are as following:
2025 2024
£ £
Not later than one year 308 1,944
Later than one year and not later than five years - 220
308 2,164
12. Ultimate Parent Undertaking and Controlling Party
The company's immediate and ultimate parent undertaking is Ariceum Therapeutics GmbH . Ariceum Therapeutics GmbH was incorporated in Germany. Copies of the group accounts may be obtained from the secretary, Robert-Rossle-Str. 10, 13125 Berlin, Germany . The ultimate controlling party is Ariceum Therapeutics GmbH who controls 100% of the shares of Theragnostics Limited .
Page 6